Nanotechnology Drug Delivery Market Driven by Relentless R&D for Personalized Medicines

Technological advancements and relentless research and development have revolutionized the healthcare sector, and in the recent times, the dependency on blockbuster drugs has shifted to personalized medicine approach. Owing to the uniqueness of an individual’s genome and immunity system, the need for nanotechnology drug delivery methods is increasing, as these methods help in delivering drugs to the exact location of therapeutic intervention inside the body. Nanotechnology drug delivery finds application in the healthcare industry pertaining to cardiovascular disorders, neurology, anti-infective, and others.

According to a recent study by Transparency Market Research, the global nanotechnology drug delivery market will expand at a robust CAGR of 12.5% during the forecast period of 2015 to 2023, reaching a valuation of US$11.9 bn by the end of 2023, considerably up from its estimated worth of US$4.1 bn in 2014.

Increase in research and development activities to formulate novel nano-medicine, growing number of startups and small and medium enterprises active in this field, and growing interest of prominent pharmaceutical companies are some of the factors favoring the global nanotechnology drug delivery market. On the other hand, stringent regulations and high cost of developing medicines via nanotechnology is hindering the market from attaining its full potential.

Which nanotechnology drug delivery market segments are most profitable?
Technology-wise, the global nanotechnology drug delivery market is segmented into liposomes, nanocrystals, micelles, nanotubes, and nanoparticles, which has been further sub-segmented into dendrimers, fullerenes, and gold nanoparticles. Among these, nanoparticles currently dominates, gaining most of the demand for dendrimers sub-segment, which is a reflection of factors such as flexibility in size, polyvalency, biocompatibility, monodispersity, and enhanced transfection properties. Nanotubes segment is also anticipated to gain demand quickly in the near future, owing to high efficiency for bio-sensing methods and health monitoring.

Application-wise, the global market for nanotechnology drug delivery is categorized into oncology, cardiovascular or physiology, neurology, immunology, and anti-infective. Presently, anti-infective category has most of the demand, favored by rising prevalence of communicable and hospital acquired infections.

Browse Report on Nanotechnology Drug Delivery Market -

Which region has the maximum demand?
The global nanotechnology drug delivery market gains the most prominent chunk of demand from the region of North America, which houses two developed countries in the U.S and Canada, wherein healthcare infrastructure is strong and adoptability of new technology is high. Europe is currently the second most lucrative region, owing to high number of research and testing facilities, particularly in the Western Europe, high economic growth of Eastern European countries, and the presence of several innovative manufacturers in this region. However, Latin America and Asia Pacific are also expected to turn into highly profitable regions in the near future.

What is the nature of competition among the market leaders?

The global nanotechnology drug delivery market is consolidated in nature, with a few companies holding the lion share. Some of these key players are Amgen, Inc., AbbVie, Inc., Novartis AG, Celgene Corp., Alkermes plc, SkyePharma, Teva Pharmaceutical Industries Ltd., and Johnson & Johnson. 


Post a Comment

Note: only a member of this blog may post a comment.

Latest Post

Market Research Reports